Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Incannex Healthcare Limited
  6. Company
    IHL   AU000000IHL8

INCANNEX HEALTHCARE LIMITED

(IHL)
  Report
Delayed Australian Stock Exchange  -  07:33:20 2023-01-30 pm EST
0.1950 AUD   +2.63%
08:02aTop Premarket Decliners
MT
01/27Public Announcement (asx : IHL) (NASDAQ: IXHL) - Form 6-K
PU
01/18Sector Update: Health Care Stocks Continue to Weaken in Late Trade
MT
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisionsFunds 
Business Summary
Logo Incannex Healthcare Limited
Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical development company. The Company is focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of generalized anxiety disorder (GAD), obstructive sleep apnea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation, rheumatoid arthritis and inflammatory bowel disease. Its drug candidates include IHL-42X, IHL-216A and HL-675A. Its IHL-42X is a combination of acetazolamide and dronabinol for treatment of OSA. Its IHL-216A is a combination of isoflurane and cannabidiol (CBD) to prevent development of TBI/concussion. Its HL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. It is also investigating the use of psilocybin assisted psychotherapy to treat GAD.
Sales per Business
20212022Delta
Medicinal Cannabinoid Products1.90100%---
AUD in Million
Sales per region
20212022Delta
Australia1.90100%---
AUD in Million
Managers
Name Title Age Since
Joel Latham CEO, Group MD & Executive Director 33 2019
Madhukar Bhalla Chief Financial Officer & Secretary 64 2021
Mark Bleackley, Dr. Chief Scientific Officer - 2020
Rosemarie Walsh Vice President-Clinical Operations - 2020
Lekhram Changoer Chief Technology Officer 54 2022
Brad Dilkes Investor Relations Contact - -
Joseph Swan Head-Finance - -
Members of the board
Name Title Age Since
Troy Valentine Independent Non-Executive Chairman 49 2017
Peter Widdows Independent Non-Executive Director 56 2018
Joel Latham CEO, Group MD & Executive Director 33 2019
George E. Anastassov, Dr. Non-Executive Director 58 2022
Robert Bruce Clark Non-Executive Director - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,292,334,028 1,083,007,449 83.8% 0 0.0% 83.8%
Shareholders
NameEquities%
Sud Agarwal 75,303,093 4.74%
George E. Anastassov 66,972,077 4.22%
Lekhram Changoer 63,954,841 4.03%
ETF Managers Group LLC 60,127,146 3.79%
Troy Valentine 36,651,198 2.31%
The Vanguard Group, Inc. 35,473,702 2.24%
Cannvalate Pty Ltd. 32,000,000 2.02%
Raymond Laurence Carroll 30,000,000 1.89%
Joel Latham 23,748,413 1.50%
Brownarrows Pty Ltd. 21,615,707 1.36%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Incannex Healthcare Limited